Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1650648 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $9.61Day −2.44%Mkt cap $478M1Y +120.4%Off 52W high −31.4%Vol (1Y) 92.9%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,360 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest22.8% of sh out |
| Days to cover15.5d |
| 13F net flow (QoQ)−3.99% |
| Top-10 13F concentration66.2% |
| Next report (est.)2026-08-07 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$88.2M |
| Earnings (TTM)-$160.9M |
| ROE−27.6% |
| Net margin−164.4% |
| Sales growth 3Y200.9% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+28.1% |
| 1Y+120.4% |
| 3Y−47.5% |
| 5Y−61.8% |
| Since incept. (ann.)−24.6% |
Total return through 2026-07-29 · series begins 2021-02-22. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)92.9% |
| Ann. volatility (3Y)96.0% |
| Sharpe (1Y)1.24 |
| Sharpe (3Y)0.21 |
| Max drawdown (1Y)−41.4% |
| Max drawdown (3Y)−93.0% |
| Beta (3Y vs SPY)3.08 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 5.2M | $49M | 10.54% | +13.2% |
| RA CAPITAL MANAGEMENT, L.P. | 5.0M | $47M | 10.14% | −10.7% |
| GOLDMAN SACHS GROUP INC | 4.2M | $39M | 8.45% | −2.3% |
| BlackRock, Inc. | 4.1M | $39M | 8.33% | +2.0% |
| NOVO HOLDINGS A/S | 3.7M | $34M | 7.33% | +0.0% |
| BVF INC/IL | 2.9M | $27M | 5.78% | −37.8% |
| STATE STREET CORP | 2.7M | $25M | 5.44% | +0.7% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.2M | $20M | 4.41% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total. Institutional 13F holdings sum to 102.2% of shares outstanding. Readings above 100% reflect securities-lending double counting: shares on loan to short sellers are reported long by both the lending institution and the one that bought them. FINRA short interest of 11,990,069 shares (settlement 2026-04-30) accounts for the excess.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-07 | −$1.01 | — | $3.0M | +21664.3% |
| 2025-12-31 | 2026-03-18 | — | — | $85.1M | +8508900.0% |
| 2025-09-30 | 2025-11-10 | −$1.01 | — | $90,000 | +2900.0% |
| 2025-06-30 | 2025-08-11 | −$0.98 | — | $15,000 | +200.0% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-07 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
JP 100% · US 0%
geographic · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
